{"id":920,"date":"2025-06-04T01:57:22","date_gmt":"2025-06-04T08:57:22","guid":{"rendered":"https:\/\/cloudbreakpharma.com\/?p=920"},"modified":"2025-06-04T02:01:33","modified_gmt":"2025-06-04T09:01:33","slug":"cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial","status":"publish","type":"post","link":"https:\/\/cloudbreakpharma.com\/zh\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\/","title":{"rendered":"\u62e8\u5eb7\u89c6\u4e91\u5168\u7403\u521b\u65b0\u773c\u79d1\u836f\u7269CBT-001\u56fd\u9645\u591a\u4e2d\u5fc3III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u5b8c\u6210\u5168\u90e8\u60a3\u8005\u5165\u7ec4"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"920\" class=\"elementor elementor-920\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-c3fe21d elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"c3fe21d\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-74f661f\" data-id=\"74f661f\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-cf824e5 elementor-widget elementor-widget-text-editor\" data-id=\"cf824e5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Cloudbreak Pharma Inc.\uff08\u62e8\u5eb7\u89c6\u4e91\uff09\u6b23\u7136\u5ba3\u5e03\uff0c\u6211\u4eec\u7ba1\u7ebf\u4e2d\u7528\u4e8e\u6cbb\u7597\u7ffc\u72b6\u80ec\u8089\u7684\u5168\u7403\u521b\u65b0\u773c\u79d1\u836f\u7269CBT-001\u5f00\u5c55\u7684\u56fd\u9645\u591a\u4e2d\u5fc3III\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8fd1\u65e5\u5b8c\u6210\u4e86\u5168\u7403\u4e2d\u5fc3\u5168\u90e8\u60a3\u8005\u5165\u7ec4\u3002\u8be5\u7814\u7a76\u662f\u4e00\u9879\u968f\u673a\u3001\u53cc\u76f2\u3001\u5b89\u6170\u5242\u5e73\u884c\u5bf9\u7167\u7684III\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u62df\u5165\u7ec4660\u4f8b12\u5468\u5c81\u53ca\u4ee5\u4e0a\u7684\u7ffc\u72b6\u80ec\u8089\u4f34\u7ed3\u819c\u5145\u8840\u60a3\u8005\uff0c\u65e8\u5728\u8bc4\u4f30CBT-001\u6ef4\u773c\u6db2\u5728\u51cf\u5c11\u7ed3\u819c\u5145\u8840\u548c\u9884\u9632\u7ffc\u72b6\u80ec\u8089\u8fdb\u5c55\u65b9\u9762\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u3002<\/p><p>CBT-001\u7531Cloudbreak Pharma Inc.\uff08\u62e8\u5eb7\u89c6\u4e91\uff09\u5f00\u53d1\uff0c\u662f\u5df2\u4e0a\u5e02\u6cbb\u7597\u80ba\u7ea4\u7ef4\u5316\u836f\u7269OFEV\u7684\u4e3b\u8981\u6210\u5206\u5c3c\u8fbe\u5c3c\u5e03\u7684\u521b\u65b0\u6539\u826f\u4ea7\u54c1\uff0c\u5bf9\u65b0\u751f\u8840\u7ba1\u751f\u6210\u548c\u7ec4\u7ec7\u7ea4\u7ef4\u5316\u5747\u6709\u6291\u5236\u4f5c\u7528\u3002\u6b64\u524d\u5df2\u5728\u7f8e\u56fd\u5b8c\u6210II\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u5b89\u5168\u6027\u9ad8\uff0c\u5177\u6709\u4e34\u5e8a\u7597\u6548\uff0c\u53ef\u6291\u5236\u7ffc\u72b6\u80ec\u8089\u751f\u957f\u5e76\u63a7\u5236\u75c5\u60c5\u8fdb\u5c55\u3002\u53ef\u7528\u4e8e\u7ffc\u72b6\u80ec\u8089\u8f7b\u4e2d\u91cd\u5ea6\u5404\u9636\u6bb5\uff0c\u53ca\u624b\u672f\u540e\u9632\u6b62\u590d\u53d1\u3002\u8fdc\u5927\u96c6\u56e2\u62e5\u6709CBT-001\u5728\u4e2d\u56fd\u5927\u9646\u3001\u4e2d\u56fd\u9999\u6e2f\u7279\u522b\u884c\u653f\u533a\u3001\u4e2d\u56fd\u6fb3\u95e8\u7279\u522b\u884c\u653f\u533a\u3001\u53ca\u4e2d\u56fd\u53f0\u6e7e\u5730\u533a\u7684\u72ec\u5bb6\u751f\u4ea7(\u542b\u6280\u672f\u8f6c\u79fb)\u53ca\u5546\u4e1a\u5316\u6743\u5229\uff0c\u6388\u6743\u8303\u56f4\u6db5\u76d6CBT-001\u7684\u5728\u7814\u9002\u5e94\u75c7\uff0c\u5373\u9884\u9632\u7ffc\u72b6\u80ec\u8089\u751f\u957f\u53ca\u51cf\u5c11\u7ed3\u819c\u5145\u8840\u3002\u62e8\u5eb7\u89c6\u4e91\u4ea6\u5c06CBT-001\u6388\u6743\u4e8e\u53c2\u5929\u5236\u836f\uff0c\u8be5\u6388\u6743\u6d89\u53ca\u65e5\u672c\u53ca\u97e9\u56fd\u3001\u8d8a\u5357\u3001\u6cf0\u56fd\u3001\u9a6c\u6765\u897f\u4e9a\u3001\u83f2\u5f8b\u5bbe\u3001\u65b0\u52a0\u5761\u548c\u5370\u5ea6\u5c3c\u897f\u4e9a\u5728\u5185\u7684\u4e1c\u5357\u4e9a\u5730\u533a\u3002\u6839\u636e\u534f\u8bae\u6761\u6b3e\uff0c\u62e8\u5eb7\u89c6\u4e91\u6388\u6743\u53c2\u5929\u5236\u836f\u5728\u8be5\u5730\u533a\u5f00\u53d1\u3001\u751f\u4ea7\u548c\u5546\u4e1a\u5316CBT-001\u836f\u54c1\u3002<\/p><p>\u7ffc\u72b6\u80ec\u8089\u662f\u4e00\u79cd\u5e38\u89c1\u7684\u6162\u6027\u708e\u75c7\u589e\u751f\u6027\u773c\u8868\u75be\u75c5\uff0c\u901a\u5e38\u53d1\u751f\u4e8e\u773c\u89d2\u90e8\u7ed3\u819c\uff0c\u9010\u6e10\u4fb5\u88ad\u81f3\u89d2\u819c\uff0c\u5f15\u8d77\u6563\u5149\u6216\u906e\u6321\u77b3\u5b54\uff0c\u4ece\u800c\u5bfc\u81f4\u89c6\u529b\u4e0b\u964d\u751a\u81f3\u81f4\u76f2\u3002\u636e\u4e16\u754c\u536b\u751f\u7ec4\u7ec7\u53d1\u5e03\u7684\u300a\u4e16\u754c\u89c6\u89c9\u62a5\u544a\u300b\u6240\u793a\uff0c\u7ffc\u72b6\u80ec\u8089\u7684\u5168\u7403\u60a3\u75c5\u7387\u4e3a10.2%\uff0c\u4e2d\u56fd\u519c\u6751\u5730\u533a\u9ad8\u8fbe33%\u3002\u6839\u636e\u76f8\u5173\u6587\u732e\uff0c\u4e2d\u56fd40\u5c81\u53ca\u4ee5\u4e0a\u4eba\u7fa4\u60a3\u75c5\u7387\u4e3a13.4%\uff0c\u4e14\u968f\u7740\u5e74\u9f84\u589e\u957f\u800c\u4e0d\u65ad\u5347\u9ad8\u3002\u76ee\u524d\u5e76\u6ca1\u6709\u6cbb\u7597\u7ffc\u72b6\u80ec\u8089\u7684\u4e13\u95e8\u836f\u7269\uff0c\u4e34\u5e8a\u4ee5\u4eba\u5de5\u6cea\u6db2\u3001\u975e\u753e\u4f53\u7c7b\u3001\u7cd6\u76ae\u8d28\u6fc0\u7d20\u6ef4\u773c\u6db2\u7b49\u6807\u7b7e\u5916\u7528\u836f\u4e3a\u4e3b\uff0c\u4f46\u73b0\u6709\u7684\u6cbb\u7597\u836f\u7269\u672a\u663e\u793a\u786e\u5207\u7597\u6548\u4e14\u5b58\u5728\u957f\u671f\u7528\u836f\u5b89\u5168\u6027\u98ce\u9669\u95ee\u9898\u3002\u4e25\u91cd\u60a3\u8005\u53ef\u901a\u8fc7\u624b\u672f\u6cbb\u7597\uff0c\u4f46\u7ffc\u72b6\u80ec\u8089\u91c7\u7528\u5de9\u819c\u5207\u9664\u672f\u540e\uff0c\u672f\u540e\u590d\u53d1\u7387\u4e3a30-80%\uff0c\u591a\u6b21\u590d\u53d1\u53ef\u9020\u6210\u7751\u7403\u7c98\u8fde\uff0c\u5f71\u54cd\u773c\u7403\u8fd0\u52a8\u3002\u53ef\u89c1\uff0c\u5bf9\u7ffc\u72b6\u80ec\u8089\u7684\u6cbb\u7597\u4ecd\u6709\u5de8\u5927\u7684\u4e34\u5e8a\u9700\u6c42\u672a\u83b7\u6ee1\u8db3\u3002<\/p><p>\u968f\u7740III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u5168\u90e8\u60a3\u8005\u5165\u7ec4\u7684\u5b9e\u73b0\uff0cCBT-001\u5411\u7740\u6210\u4e3a\u5168\u7403\u9996\u4e2a\u7ffc\u72b6\u80ec\u8089\u4e13\u95e8\u6cbb\u7597\u836f\u7269\u7684\u76ee\u6807\u8fc8\u51fa\u4e86\u5173\u952e\u4e00\u6b65\u3002\u62e8\u5eb7\u89c6\u4e91\u5c06\u7ee7\u7eed\u5bc6\u5207\u5173\u6ce8\u8bd5\u9a8c\u8fdb\u5c55\uff0c\u786e\u4fdd\u7814\u7a76\u7684\u987a\u5229\u63a8\u8fdb\u3002\u6211\u4eec\u671f\u5f85\u8fd9\u9879\u521b\u65b0\u7597\u6cd5\u80fd\u591f\u65e9\u65e5\u5b8c\u6210\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u4e3a\u5168\u7403\u6570\u4ebf\u7ffc\u72b6\u80ec\u8089\u60a3\u8005\u5e26\u6765\u5b89\u5168\u6709\u6548\u7684\u6cbb\u7597\u9009\u62e9\uff0c\u586b\u8865\u8fd9\u4e00\u91cd\u8981\u533b\u7597\u9886\u57df\u7684\u7a7a\u767d\u3002\u540c\u65f6\uff0c\u901a\u8fc7\u4e0e\u8fdc\u5927\u96c6\u56e2\u548c\u53c2\u5929\u5236\u836f\u7684\u6218\u7565\u5408\u4f5c\uff0c\u6211\u4eec\u6709\u4fe1\u5fc3\u5c06\u8fd9\u4e00\u521b\u65b0\u6210\u679c\u60e0\u53ca\u4e9a\u592a\u5730\u533a\u5e7f\u5927\u60a3\u8005\uff0c\u4e3a\u6539\u5584\u5168\u7403\u773c\u5065\u5eb7\u505a\u51fa\u79ef\u6781\u8d21\u732e\u3002<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Cloudbreak Pharma Inc. is pleased to announce that our pipeline CBT-001, the global innovative ophthalmic drug for the treatment of pterygium has recently completed the enrollment of all patients in global centers in its international multicenter Phase III clinical trial. This study is a randomized, double-blind, placebo-controlled Phase III clinical trial, planning to enroll 660 [&hellip;]<\/p>\n","protected":false},"author":16,"featured_media":736,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-920","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cloudbreak Pharma\u2019s Global Innovative Ophthalmic Pipeline CBT-001 Completes the Enrollment of All Patients in the International Multi-Center Phase III Clinical Trial - Cloudbreak Pharma, Inc.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cloudbreakpharma.com\/zh\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cloudbreak Pharma\u2019s Global Innovative Ophthalmic Pipeline CBT-001 Completes the Enrollment of All Patients in the International Multi-Center Phase III Clinical Trial - Cloudbreak Pharma, Inc.\" \/>\n<meta property=\"og:description\" content=\"Cloudbreak Pharma Inc. is pleased to announce that our pipeline CBT-001, the global innovative ophthalmic drug for the treatment of pterygium has recently completed the enrollment of all patients in global centers in its international multicenter Phase III clinical trial. This study is a randomized, double-blind, placebo-controlled Phase III clinical trial, planning to enroll 660 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cloudbreakpharma.com\/zh\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Cloudbreak Pharma, Inc.\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-04T08:57:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-04T09:01:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2023\/10\/f406cb5a7d1249474969aa8465fcf43.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1363\" \/>\n\t<meta property=\"og:image:height\" content=\"575\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"James Gilbert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"James Gilbert\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\\\/\"},\"author\":{\"name\":\"James Gilbert\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/person\\\/9233f32eb4e35bf16080d902fbbd20d3\"},\"headline\":\"Cloudbreak Pharma\u2019s Global Innovative Ophthalmic Pipeline CBT-001 Completes the Enrollment of All Patients in the International Multi-Center Phase III Clinical Trial\",\"datePublished\":\"2025-06-04T08:57:22+00:00\",\"dateModified\":\"2025-06-04T09:01:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\\\/\"},\"wordCount\":582,\"publisher\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/f406cb5a7d1249474969aa8465fcf43.jpeg\",\"articleSection\":[\"News\"],\"inLanguage\":\"zh-CN\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\\\/\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\\\/\",\"name\":\"Cloudbreak Pharma\u2019s Global Innovative Ophthalmic Pipeline CBT-001 Completes the Enrollment of All Patients in the International Multi-Center Phase III Clinical Trial - Cloudbreak Pharma, Inc.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/f406cb5a7d1249474969aa8465fcf43.jpeg\",\"datePublished\":\"2025-06-04T08:57:22+00:00\",\"dateModified\":\"2025-06-04T09:01:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\\\/#breadcrumb\"},\"inLanguage\":\"zh-CN\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-CN\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/f406cb5a7d1249474969aa8465fcf43.jpeg\",\"contentUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/f406cb5a7d1249474969aa8465fcf43.jpeg\",\"width\":1363,\"height\":575},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/cloudbreakpharma.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cloudbreak Pharma\u2019s Global Innovative Ophthalmic Pipeline CBT-001 Completes the Enrollment of All Patients in the International Multi-Center Phase III Clinical Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/\",\"name\":\"Cloudbreak Pharma, Inc.\",\"description\":\"Seeing Life Better Through Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cloudbreakpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-CN\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#organization\",\"name\":\"Cloudbreak Pharma, Inc.\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-CN\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/cloudbreak-logo.svg\",\"contentUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/cloudbreak-logo.svg\",\"width\":824,\"height\":199,\"caption\":\"Cloudbreak Pharma, Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/person\\\/9233f32eb4e35bf16080d902fbbd20d3\",\"name\":\"James Gilbert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-CN\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g\",\"caption\":\"James Gilbert\"},\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/zh\\\/author\\\/jgdm18gmail-com\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cloudbreak Pharma\u2019s Global Innovative Ophthalmic Pipeline CBT-001 Completes the Enrollment of All Patients in the International Multi-Center Phase III Clinical Trial - Cloudbreak Pharma, Inc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cloudbreakpharma.com\/zh\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\/","og_locale":"zh_CN","og_type":"article","og_title":"Cloudbreak Pharma\u2019s Global Innovative Ophthalmic Pipeline CBT-001 Completes the Enrollment of All Patients in the International Multi-Center Phase III Clinical Trial - Cloudbreak Pharma, Inc.","og_description":"Cloudbreak Pharma Inc. is pleased to announce that our pipeline CBT-001, the global innovative ophthalmic drug for the treatment of pterygium has recently completed the enrollment of all patients in global centers in its international multicenter Phase III clinical trial. This study is a randomized, double-blind, placebo-controlled Phase III clinical trial, planning to enroll 660 [&hellip;]","og_url":"https:\/\/cloudbreakpharma.com\/zh\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\/","og_site_name":"Cloudbreak Pharma, Inc.","article_published_time":"2025-06-04T08:57:22+00:00","article_modified_time":"2025-06-04T09:01:33+00:00","og_image":[{"width":1363,"height":575,"url":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2023\/10\/f406cb5a7d1249474969aa8465fcf43.jpeg","type":"image\/jpeg"}],"author":"James Gilbert","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005":"James Gilbert","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"3 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\/#article","isPartOf":{"@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\/"},"author":{"name":"James Gilbert","@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/person\/9233f32eb4e35bf16080d902fbbd20d3"},"headline":"Cloudbreak Pharma\u2019s Global Innovative Ophthalmic Pipeline CBT-001 Completes the Enrollment of All Patients in the International Multi-Center Phase III Clinical Trial","datePublished":"2025-06-04T08:57:22+00:00","dateModified":"2025-06-04T09:01:33+00:00","mainEntityOfPage":{"@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\/"},"wordCount":582,"publisher":{"@id":"https:\/\/cloudbreakpharma.com\/#organization"},"image":{"@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2023\/10\/f406cb5a7d1249474969aa8465fcf43.jpeg","articleSection":["News"],"inLanguage":"zh-CN"},{"@type":"WebPage","@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\/","url":"https:\/\/cloudbreakpharma.com\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\/","name":"Cloudbreak Pharma\u2019s Global Innovative Ophthalmic Pipeline CBT-001 Completes the Enrollment of All Patients in the International Multi-Center Phase III Clinical Trial - Cloudbreak Pharma, Inc.","isPartOf":{"@id":"https:\/\/cloudbreakpharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\/#primaryimage"},"image":{"@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2023\/10\/f406cb5a7d1249474969aa8465fcf43.jpeg","datePublished":"2025-06-04T08:57:22+00:00","dateModified":"2025-06-04T09:01:33+00:00","breadcrumb":{"@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\/#breadcrumb"},"inLanguage":"zh-CN","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cloudbreakpharma.com\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\/"]}]},{"@type":"ImageObject","inLanguage":"zh-CN","@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\/#primaryimage","url":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2023\/10\/f406cb5a7d1249474969aa8465fcf43.jpeg","contentUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2023\/10\/f406cb5a7d1249474969aa8465fcf43.jpeg","width":1363,"height":575},{"@type":"BreadcrumbList","@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cloudbreakpharma.com\/"},{"@type":"ListItem","position":2,"name":"Cloudbreak Pharma\u2019s Global Innovative Ophthalmic Pipeline CBT-001 Completes the Enrollment of All Patients in the International Multi-Center Phase III Clinical Trial"}]},{"@type":"WebSite","@id":"https:\/\/cloudbreakpharma.com\/#website","url":"https:\/\/cloudbreakpharma.com\/","name":"Cloudbreak Pharma, Inc.","description":"\u533b\u836f\u4f7f\u6211\u4eec\u80fd\u66f4\u597d\u7684\u89c6\u89c9\u4eab\u53d7\u751f\u6d3b","publisher":{"@id":"https:\/\/cloudbreakpharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cloudbreakpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-CN"},{"@type":"Organization","@id":"https:\/\/cloudbreakpharma.com\/#organization","name":"Cloudbreak Pharma, Inc.","url":"https:\/\/cloudbreakpharma.com\/","logo":{"@type":"ImageObject","inLanguage":"zh-CN","@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/logo\/image\/","url":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2022\/08\/cloudbreak-logo.svg","contentUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2022\/08\/cloudbreak-logo.svg","width":824,"height":199,"caption":"Cloudbreak Pharma, Inc."},"image":{"@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/person\/9233f32eb4e35bf16080d902fbbd20d3","name":"James Gilbert","image":{"@type":"ImageObject","inLanguage":"zh-CN","@id":"https:\/\/secure.gravatar.com\/avatar\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g","caption":"James Gilbert"},"url":"https:\/\/cloudbreakpharma.com\/zh\/author\/jgdm18gmail-com\/"}]}},"_links":{"self":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/posts\/920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/comments?post=920"}],"version-history":[{"count":0,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/posts\/920\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/media\/736"}],"wp:attachment":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/media?parent=920"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/categories?post=920"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/tags?post=920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}